Join
Live feed
·
PRReleasevia Quantisnow
Invivyd Inc. logo

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

ByQuantisnow·Wall Street's wire, on your screen.
IVVD· Invivyd Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IVVD (Invivyd Inc.) and more on Quantisnow.